Virtual event attended by life sciences industry professionals aimed at transforming
and digitalizing the life sciences industry in India
Innovation-driven event focused on addressing challenges in pharma, biopharma,
medical devices and patient care segments
Speakers from Biocon, IPCA, Skanray, Sahajanand Medical Technologies, Lupin,
Agappe Diagnostics, Stryker, Brainsight, COMOFI Medtech, HCL Technologies and
Jamia Milia Islamia University shared their knowledge and know-how
Bangalore, Karnataka, India — June 23, 2020 — Dassault Systèmes (Euronext Paris: #13065,
DSY.PA) hosted today “The World After: From Things to Life 2020,” a one-of-a-kind virtual
conference that provided in-depth insights into the vast potential of the life sciences industry
in India. With a deep understanding of the current challenges facing pharmaceutical, biotech
and medical device companies, and the patient care sector, Dassault Systèmes hosted the
event as part of its commitment to help advance the pace of discovery of new drugs and
medicines and deliver holistic, superior patient and physician-centric experiences.
“The World After – From Things to Life” focused on transforming and digitalizing the life
sciences industry in India, which is undergoing core shifts in business processes and
manufacturing operations to make it more agile and adaptable, reinventing the value chain,
capitalizing knowledge and strategic planning, adhering to regulatory frameworks, and
introducing futuristic and advanced technological solutions.
Addressing the business challenges of the life sciences industry, Dassault Systèmes
demonstrated the “License to Cure for Biopharma,” “ONE Lab,” and “Accelerated Device”
industry solution experiences based on the 3DEXPERIENCE platform. In the tracks of the
virtual event, several global and local life sciences industry experts and startups shared their
experiences.
The pharma segment of the event covered topics like digital continuity in the pharmaceutical
industry, revolutionizing the drug development process with artificial intelligence, design and
development of SARS-CoV-2 main protease inhibitors, optimizing laboratories and leveraging
knowledge to improve time to market. Pharma and biopharma companies are moving
towards unified platforms that help in drug research and discovery enhancing the ecosystemresearch, development, manufacturing and quality and compliance. “Dassault Systèmes’
solution for quality control labs greatly reduced data input, transcription, and integrity
validation efforts increased the overall productivity of the lab,” said Ashok Nayak, CIO, IPCA
Laboratories.
The patient care segment in the event discussed “In-Silico in healthcare,” optimizing efficacy
and safety for medical devices, simulation-driven new product development (NPD),
simulation for understanding the functional dynamics of the brain and therapeutic
stimulations using AI. The patient care sector is changing rapidly with a focus on improving
patient outcomes and a shift from intermittent treatments to a continuous engagement
driven by simulation technologies. “Multiphysics simulation capabilities have helped in the
indigenous research and development of minimally invasive coronary stent systems as well
as in maximizing their life and performance,” said Dr. Ramanan Lakshminarayanan, Chief
Technology Officer, Sahajanand Medical Technologies.
The medical devices segment in the event highlighted faster time to market of innovative
medical devices, and key technology solutions adopted in the diagnostics segment. Medical
device manufacturers are moving away from point solutions for mechanical and electrical
design, simulation, product data management (PDM) and technical communication, and
toward integrated product development platforms to introduce product faster into the
market and improve the overall performance and reliability, which is always the big challenge
for them. “Medical Device manufacturers have to embrace digital technology to overcome
the challenges in the manufacturing, product delivery, supply chain etc., which used to be an
option in the past; now it is a must to sustain in the market and be innovative,” said
Vishwaprasad Alva, Managing Director, Skanray.
“The World After – From Things to Life” also featured the 3DEXPERIENCE playground, which
showcased innovations on industry-leading brands like SOLIDWORKS, BIOVIA and SIMULIA
with virtual experiences and technology demos of the internet of things, artificial intelligence,
machine leaning and data analytics applicable in the life sciences industry.
“We intend to be a catalyst and technology enabler behind all the new opportunities evolving
in the life sciences industry in India,” said Deepak NG, Managing Director, India, Dassault
Systemes. “We are born out of science and expertise in engineering. We want to bridge
medical science and engineering into the domains of manufacturing of medical devices, to
offering scientific applications on the 3DEXPERIENCE platform for drug research, discovery
and manufacturing, to simulating treatments. Earlier this year, Dassault Systèmes announced
its strategic direction for the coming years, extending its focus from things to life. We want
to transform how people are cured and help them live a better life.”
Dassault Systèmes Demonstrates Innovations for the Life Sciences Industry in India at the “The World After – From Things to Life” Virtual Event
